Novo Nordisk/X
Aug 2, 2025, 03:50
FDA Approves Novo Nordisk Prophylactic Treatment for Hemophilia A and B
Novo Nordisk US has shared a proud post on X:
“PRESS: Novo Nordisk receives US FDA approval for a new indication for a prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults and children 12 years and older with hemophilia A or B without inhibitors. ”
To learn more, follow the link.
Stay informed with Hemostasis Today.
-
Aug 26, 2026, 18:38Maia Meier: Muhiba’s Story of Courage, Resilience and Hope With Type 3 VWD
-
Aug 26, 2026, 18:27Isabella Presch: Not Every Genome-Editing Program Needs to Start From Zero
-
Aug 26, 2026, 18:24New Educational Content for the Bleeding Disorders Community – EAHAD
-
Aug 26, 2026, 18:14N. Mariana S. Vasquez: From Skin and Gut to Celiac Disease
-
Aug 26, 2026, 18:13Francesca Granata: What Happens When Patients Become Researchers and Researchers Become Advocates?
-
Aug 26, 2026, 18:11Maxima Mendez: Statins Are No Longer the Whole Story
-
Aug 26, 2026, 18:06Ashkan Shoamanesh: ANNEXa-I Analyses Inform Individualized Treatment in Intracranial Hemorrhage
-
Aug 26, 2026, 18:01Sam Tsimikas: Lp(a) and Oxidized Phospholipids Reveal a New Link Between Hypercoagulability and Stronger Clot Formation
-
Aug 26, 2026, 17:52Kamlesh Darji: A Practical Guide to Interpreting Coagulation Tests